<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03991013</url>
  </required_header>
  <id_info>
    <org_study_id>ARTIST</org_study_id>
    <nct_id>NCT03991013</nct_id>
  </id_info>
  <brief_title>Tenofovir-lamivudine-dolutegravir Combination as Second-line ART: a Randomised Controlled Trial</brief_title>
  <acronym>ARTIST</acronym>
  <official_title>AntiRetroviral Therapy In Second-line: Investigating Tenofovir-lamivudine-dolutegravir (ARTIST): a Randomised Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Cape Town</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Wellcome Trust</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Médecins Sans Frontières, Belgium</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Cape Town</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The strategy to support virological suppression on second-line antiretroviral treatment (ART)&#xD;
      includes the provision of ART that has a low pill burden, good tolerability, low toxicity, is&#xD;
      easily monitored, has a high barrier to resistance, and that is low cost. The fixed-dose&#xD;
      combination of tenofovir-lamivudine-dolutegravir offers significant advantage as a potential&#xD;
      second-line regimen compared to the World Health Organization standard of care second-line&#xD;
      regimen of zidovudine-lamivudine-dolutegravir, in terms of cost, tolerability and monitoring&#xD;
      requirements.&#xD;
&#xD;
      The ARTIST study is a phase 2, randomised, double-blind, placebo-controlled trial aiming to&#xD;
      determine the proportion of patients achieving virological suppression when recycling the&#xD;
      tenofovir-emtricitabine/lamivudine backbone with dolutegravir&#xD;
      (tenofovir-lamivudine-dolutegravir fixed-dose combination) as a second-line with and without&#xD;
      a lead-in supplementary dose of dolutegravir, in patients failing a&#xD;
      tenofovir-emtricitabine/lamivudine-efavirenz first-line regimen.&#xD;
&#xD;
      There is evidence to suggest that even in the presence of resistance mutations to tenofovir&#xD;
      and lamivudine (K65R or M184V/I), using this backbone with dolutegravir will provide an&#xD;
      effective second-line regimen in patients who have failed a first-line regimen of&#xD;
      tenofovir-emtricitabine/lamivudine-efavirenz. The strategy of giving a lead-in supplementary&#xD;
      dose of dolutegravir is in view of the inducing effect of efavirenz on dolutegravir&#xD;
      metabolism and transport that persists for 2 weeks after efavirenz is stopped; the inducing&#xD;
      effect decreases with time after efavirenz is stopped.&#xD;
&#xD;
      Given that these patients will have elevated viral loads, a high baseline risk of nucleoside&#xD;
      reverse transcriptase inhibitor (NRTI) resistance and efavirenz resistance, and the inducing&#xD;
      effect of efavirenz on dolutegravir metabolism and transport that persists for 2 weeks, this&#xD;
      study will comprise two stages. The first stage will evaluate virological suppression in 62&#xD;
      participants initiated on the fixed-dose combination of tenofovir-lamivudine-dolutegravir&#xD;
      with a lead-in supplementary dose of dolutegravir for the first 14 days. The study will&#xD;
      progress to the second stage if this strategy proves effective, and 130 participants will&#xD;
      then be randomised to receive the fixed-dose combination of tenofovir-lamivudine-dolutegravir&#xD;
      with and without this lead-in dose.&#xD;
&#xD;
      The primary endpoint is virological suppression (viral load &lt;50 copies/mL) at 24 weeks.&#xD;
&#xD;
      A pharmacokinetic sub-study will be conducted on 12 participants in stage 1 and 24&#xD;
      participants in stage 2, to assess the trough concentrations of dolutegravir and&#xD;
      off-treatment concentrations of efavirenz at day 3, 7, 14, and 28. This is to evaluate the&#xD;
      need for the lead-in supplementary dose of dolutegravir.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 8, 2019</start_date>
  <completion_date type="Anticipated">October 2022</completion_date>
  <primary_completion_date type="Anticipated">April 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>This study will be a phase 2, randomised, double-blind, placebo-controlled trial of tenofovir-lamivudine-dolutegravir fixed-dose combination daily with a lead-in supplementary 50 mg dose of dolutegravir versus matching placebo taken 12 hours later for the first 14 days in patients failing a first-line tenofovir-emtricitabine/lamivudine-efavirenz regimen.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Virological suppression at 24 weeks</measure>
    <time_frame>24 weeks</time_frame>
    <description>Proportion of participants with HIV viral load &lt;50 copies/mL at 24 weeks analysed by modified intention to treat (ITT) and according to the FDA snapshot algorithm, overall and stratified by the presence or absence of resistance to tenofovir and lamivudine at baseline.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Antiretroviral resistance mutations by genotypic resistance testing</measure>
    <time_frame>Baseline, 24 and 48 weeks</time_frame>
    <description>To describe resistance profile at baseline (NRTI and efavirenz resistance), and treatment-emergent resistance to integrase inhibitor and NRTI in participants who experience virological failure.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Residual efavirenz concentrations and dolutegravir trough concentrations</measure>
    <time_frame>First 28 days</time_frame>
    <description>To evaluate the trough concentrations (ng/mL) of dolutegravir and the residual concentrations (ng/mL) of efavirenz in the period after switching regimens. To evaluate the proportion of participants with dolutegravir trough concentrations above the protein-adjusted 90% inhibitory concentration (PA-IC90) value at all pharmacokinetics time points.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Virological suppression at 12 and 48 weeks (modified ITT)</measure>
    <time_frame>12 and 48 weeks</time_frame>
    <description>Proportion of participants with HIV viral load &lt;50 copies/mL at 12 and 48 weeks analysed by modified ITT.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Virological suppression at 12, 24 and 48 weeks (per protocol)</measure>
    <time_frame>12, 24 and 48 weeks</time_frame>
    <description>Proportion of participants with HIV viral load &lt;50 copies/mL at 12, 24 and 48 weeks analysed per protocol.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adherence to treatment</measure>
    <time_frame>24 and 48 weeks</time_frame>
    <description>To describe tenofovir-diphosphate concentration (ng/mL) in participants who experience virological failure and matched controls from among those who are suppressed at 24 and 48 weeks.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CD4 change at 24 and 48 weeks</measure>
    <time_frame>24 and 48 weeks</time_frame>
    <description>Change in CD4 count from screening at week 24 and 48.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>48 weeks</time_frame>
    <description>To describe grade 3 and 4 drug-related adverse events, serious adverse events, and any adverse event requiring discontinuation of any drug in the ART regimen.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All-cause mortality</measure>
    <time_frame>48 weeks</time_frame>
    <description>To describe all-cause mortality.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">192</enrollment>
  <condition>HIV Infections</condition>
  <arm_group>
    <arm_group_label>Supplementary dose</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Tenofovir-lamivudine-dolutegravir fixed-dose combination tablet daily with an additional dolutegravir 50 mg dose taken 12 hours later for the first 14 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo dose</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Tenofovir-lamivudine-dolutegravir fixed-dose combination tablet daily with a matching placebo taken 12 hours later for the first 14 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dolutegravir 50 mg</intervention_name>
    <description>Tenofovir-lamivudine-dolutegravir fixed-dose combination tablet with a lead-in supplementary dose of 50 mg dolutegravir taken 12 hours later for the first 14 days, with continuation of tenofovir-lamivudine-dolutegravir for the duration of the study (48 weeks).</description>
    <arm_group_label>Supplementary dose</arm_group_label>
    <other_name>Dalimune 50 mg</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Tenofovir-lamivudine-dolutegravir fixed-dose combination tablet with a matching placebo taken 12 hours later for the first 14 days, with continuation of tenofovir-lamivudine-dolutegravir for the duration of the study (48 weeks).</description>
    <arm_group_label>Placebo dose</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        HIV positive patients over 18 years old, who have failed first-line ART regimen of&#xD;
        tenofovir-emtricitabine/lamivudine-efavirenz, are able to attend the study clinic for one&#xD;
        year of scheduled visits and who have given written, informed consent will be enrolled in&#xD;
        this study. In female patients of child-bearing potential, those willing to use effective&#xD;
        and reliable contraception for the duration of the study will be eligible.&#xD;
&#xD;
        Failure of a first-line regimen is defined as a viral load (VL) of &gt;1000 copies/mL (within&#xD;
        the previous two months) and an immediately prior VL &gt;1000 copies/mL, taken 2-24 months&#xD;
        prior (based on data captured by National Health Laboratory Service).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  If the patient has two VLs 2-3 months apart: &gt;2 log drop in VLs between the most&#xD;
             recent VL (within the previous two months) and the immediately prior VL (taken 2-3&#xD;
             months prior)&#xD;
&#xD;
          -  CD4 count &lt;100 cells/microlitre&#xD;
&#xD;
          -  Estimated glomerular filtration rate (eGFR) &lt;50 mL/min/1.73 m2 using the Modification&#xD;
             of Diet in Renal Disease (MDRD) formula&#xD;
&#xD;
          -  Alanine aminotransferase &gt;100 U/L or total bilirubin &gt;twice the upper limit of normal&#xD;
&#xD;
          -  Pregnant or desire to become pregnant during the study period (48 weeks)&#xD;
&#xD;
          -  Breastfeeding&#xD;
&#xD;
          -  Being treated for active tuberculosis (TB) or concern that patient has undiagnosed&#xD;
             active TB (based on symptom screening) as rifampicin reduces the concentrations of&#xD;
             dolutegravir and thus requires dose adjustments&#xD;
&#xD;
          -  Any current diagnosis of malignancy&#xD;
&#xD;
          -  Allergy or intolerance to one of the drugs in regimen&#xD;
&#xD;
          -  Active, severe psychiatric disease judged likely to impact adherence&#xD;
&#xD;
          -  Current substance abuse judged likely to impact adherence&#xD;
&#xD;
          -  On treatment for AIDS-defining condition (not including secondary prophylaxis&#xD;
             maintenance therapy)&#xD;
&#xD;
          -  Any other clinical condition that in the opinion of an investigator puts the patient&#xD;
             at increased risk if participating in the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Graeme Meintjes, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Cape Town</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Claire Keene</last_name>
    <role>Principal Investigator</role>
    <affiliation>Médecins Sans Frontières, Belgium</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Graeme Meintjes, PhD</last_name>
    <phone>+27214066075</phone>
    <email>graeme.meintjes@uct.ac.za</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Claire Keene</last_name>
    <phone>+27663477892</phone>
    <email>msfocb-khayelitsha-hivmam@brussels.msf.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Khayelitsha Site B/Ubuntu Community Health Clinic</name>
      <address>
        <city>Cape Town</city>
        <state>Western Cape</state>
        <zip>8001</zip>
        <country>South Africa</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ying Zhao, MMed</last_name>
      <phone>+27738159538</phone>
      <email>zhxyin001@myuct.ac.za</email>
    </contact>
    <investigator>
      <last_name>Graeme Meintjes, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ying Zhao, MMed</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>South Africa</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>May 31, 2019</study_first_submitted>
  <study_first_submitted_qc>June 16, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 19, 2019</study_first_posted>
  <last_update_submitted>April 28, 2021</last_update_submitted>
  <last_update_submitted_qc>April 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Cape Town</investigator_affiliation>
    <investigator_full_name>Graeme Meintjes</investigator_full_name>
    <investigator_title>Professor of Medicine, University of Cape Town (UCT)</investigator_title>
  </responsible_party>
  <keyword>second line antiretroviral therapy</keyword>
  <keyword>dolutegravir</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dolutegravir</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Data will be shared with other organisations or individuals for further research upon a reasonable request to the University of Cape Town PI, provided that certain conditions are met (including but not limited to the ethical standards upheld by Human Research Ethics Committee (HREC) that approved the initial study).</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>From the time the final results are published</ipd_time_frame>
    <ipd_access_criteria>Data will be shared with other organisations or individuals for further research upon a reasonable request to the University of Cape Town PI, provided that certain conditions are met (including but not limited to the ethical standards upheld by HREC that approved the initial study).</ipd_access_criteria>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>June 17, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/13/NCT03991013/Prot_005.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>December 19, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/13/NCT03991013/SAP_002.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>June 17, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/13/NCT03991013/ICF_006.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

